Functional role of high-affinity anandamide transport, as revealed by selective inhibition

Science

Volumn 277, Issue 5329, 1997, Pages 1094-1097

  Beltramo, M ^a   Stella, N ^a   Calignano, A ^b   Lin, S Y ^c   Makriyannis, A ^c   Piomelli, D ^a  

^a NEUROSCIENCES INSTITUTE   (United States)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANANDAMIDE;

ARTICLE; ASTROCYTE; BINDING SITE; DEPOLARIZATION; NONHUMAN; PHOSPHOLIPID MEMBRANE; PRIORITY JOURNAL; RECEPTOR AFFINITY; SEQUENCE HOMOLOGY; TEMPERATURE DEPENDENCE;

ANALGESICS; ANIMALS; ARACHIDONIC ACIDS; ASTROCYTES; BIOLOGICAL TRANSPORT; BROMCRESOL GREEN; CANNABINOIDS; CELLS, CULTURED; CYCLIC AMP; FORSKOLIN; MALE; MICE; MORPHOLINES; NAPHTHALENES; NEURONS; PIPERIDINES; POLYUNSATURATED ALKAMIDES; PYRAZOLES; RATS; RECEPTORS, CANNABINOID; RECEPTORS, DRUG;

EID: 0030865871     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.277.5329.1094     Document Type: Article

References (41)

1. W. A. Devane et al., Science 258, 1946 (1992); R. Mechoulam, L. Hanuš, B. R. Martin, Biochem. Pharmacol. 48, 1537 (1994).
2. W. A. Devane et al., Science 258, 1946 (1992); R. Mechoulam, L. Hanuš, B. R. Martin, Biochem. Pharmacol. 48, 1537 (1994).
3. W. L. Dewey, Pharmacol. Rev. 38, 151 (1986).
4. V. Di Marzo et al., Nature 372, 686 (1994).
5. H. Cadas, S. Gaillet, M. Beltramo, L. Venance, D. Piomelli, J. Neurosci. 16, 3934 (1996); T. Sugiura et al., Eur. J. Biochem. 240, 53 (1996); H. Cadas, E. di Tomaso, D. Piomelli, J. Neurosci., 17, 1226 (1997).
6. H. Cadas, S. Gaillet, M. Beltramo, L. Venance, D. Piomelli, J. Neurosci. 16, 3934 (1996); T. Sugiura et al., Eur. J. Biochem. 240, 53 (1996); H. Cadas, E. di Tomaso, D. Piomelli, J. Neurosci., 17, 1226 (1997).
7. H. Cadas, S. Gaillet, M. Beltramo, L. Venance, D. Piomelli, J. Neurosci. 16, 3934 (1996); T. Sugiura et al., Eur. J. Biochem. 240, 53 (1996); H. Cadas, E. di Tomaso, D. Piomelli, J. Neurosci., 17, 1226 (1997).
8. D. G. Deutsch and S. Chin, Biochem. Pharmacol. 46, 791 (1993); F. Desarnaud, H. Cadas, D. Piomelli, J. Biol. Chem. 270, 6030 (1995) ; N. Ueda, Y. Kurahashi, S. Yamamoto, T. Tokunaga, ibid., p. 23823.
9. D. G. Deutsch and S. Chin, Biochem. Pharmacol. 46, 791 (1993); F. Desarnaud, H. Cadas, D. Piomelli, J. Biol. Chem. 270, 6030 (1995) ; N. Ueda, Y. Kurahashi, S. Yamamoto, T. Tokunaga, ibid., p. 23823.
10. D. G. Deutsch and S. Chin, Biochem. Pharmacol. 46, 791 (1993); F. Desarnaud, H. Cadas, D. Piomelli, J. Biol. Chem. 270, 6030 (1995) ; N. Ueda, Y. Kurahashi, S. Yamamoto, T. Tokunaga, ibid., p. 23823.
11. B. Cravatt et al., Nature 384, 83 (1996).
12. W. D. Stein, Channels and Pumps. An Introduction to Membrane Transport, (Academic Press, San Diego, 1990), pp. 53-57.
13. L. Z. Bito, Nature 256, 1234 (1975); J. E. Schaffer and H. F. Lodish, Cell 79, 427 (1994); I. N. Bojesen and E. Bojesen, Acta Physiol. Scand. 156, 501 (1996).
14. L. Z. Bito, Nature 256, 1234 (1975); J. E. Schaffer and H. F. Lodish, Cell 79, 427 (1994); I. N. Bojesen and E. Bojesen, Acta Physiol. Scand. 156, 501 (1996).
15. L. Z. Bito, Nature 256, 1234 (1975); J. E. Schaffer and H. F. Lodish, Cell 79, 427 (1994); I. N. Bojesen and E. Bojesen, Acta Physiol. Scand. 156, 501 (1996).
16. N. Kanai et al., Science 268, 866 (1995).
17. 3H]anandamide. We subtracted nonspecific accumulation (measured at 0° to 4°C) before determining kinetic constants by Lineweaver-Burk analysis.
18. M. Beltramo and D. Piomelli, unpublished data.
19. 3H]anandamide used.
20. M. Beltramo, E. di Tomaso, D. Piomelli, FEBS Lett. 403, 263 (1997).
21. B. Koutek et al., J. Biol. Chem. 269, 22937 (1994).
22. L. Z. Bito, H. Davson, E. V. Salvador, J. Physiol. 256, 257 (1976); W. Stremmel and P. D. Berk, Proc. Natl. Acad. Sci. U.S.A. 83, 3086 (1986) ; S. Ruetz and P. Gros, Cell 77, 1071 (1994).
23. L. Z. Bito, H. Davson, E. V. Salvador, J. Physiol. 256, 257 (1976); W. Stremmel and P. D. Berk, Proc. Natl. Acad. Sci. U.S.A. 83, 3086 (1986) ; S. Ruetz and P. Gros, Cell 77, 1071 (1994).
24. L. Z. Bito, H. Davson, E. V. Salvador, J. Physiol. 256, 257 (1976); W. Stremmel and P. D. Berk, Proc. Natl. Acad. Sci. U.S.A. 83, 3086 (1986) ; S. Ruetz and P. Gros, Cell 77, 1071 (1994).
25. m values were 0.24 and 0.25 μM, respectively (n = 6).
26. 3H]ethanolamine it was 644 ± 100 dpm per well (n = 6).
27. 2; 171 Ci/mmol, New England Nuclear). After rinsing with Krebs buffer containing BSA, we subjected the cells to lipid extraction and counted radioactivity in the extracts. On average, neurons contained 245 ± 65 dpm per well and astrocytes 302 ± 20 dpm per well; nonspecific accumulation in astrocytes at 0° to 4°C was 355 ± 28 dpm per well (n = 6).
28. A. Khanolkar et al., J. Med. Chem. 39, 4515 (1996).
29. max values were 29 pmol/min per milligram of protein without AM404 and 26 pmol/min per milligram of protein with AM404, respectively (n = 6).
30. M. Herkenham et al., Proc. Natl. Acad. Sci. U.S.A. 87, 1932 (1990); L. A. Matsuda, T. I. Bonner, S. J. Lolait, J. Comp. Neurol. 327, 535 (1993).
31. M. Herkenham et al., Proc. Natl. Acad. Sci. U.S.A. 87, 1932 (1990); L. A. Matsuda, T. I. Bonner, S. J. Lolait, J. Comp. Neurol. 327, 535 (1993).
32. A. C. Howlett, J. M. Qualy, L. L. Khachatran, Mol. Pharmacol. 29, 307 (1986); M. Jung et al., J. Neurochem. 68, 402 (1997).
33. A. C. Howlett, J. M. Qualy, L. L. Khachatran, Mol. Pharmacol. 29, 307 (1986); M. Jung et al., J. Neurochem. 68, 402 (1997).
34. Cortical neurons were prepared in 12-well plates and used after 4 to 6 days in vitro. Incubations were carried out in the presence of forskolin (3 μM) and isobutyl methyl xanthine (1 mM). The cAMP concentrations were measured by radioimmunoassay with a commercial kit (Amersham, Arlington, IL) and following manufacturer's instructions.
35. L. Prézeau et al., Proc. Natl. Acad. Sci. U.S.A. 89, 8040 (1992).
36. R. Maki, M. B. Robinson, M. A. Dichter, J. Neurosci. 14, 6754 (1994).
37. The amounts of cAMP in the presence of a concentration of WIN-55212-2 below threshold (1 nM, determined in preliminary experiments) were 96.7 ± 2.5% of forskolin alone and were not significantly affected by 10 μM AM404 (89.8 ± 2.6%), 10 μM AM403 (92.4 ± 2.3%), or 10 μM bromcresol green (92.9 ± 2.3%) (n = 3). In the presence of a concentration of glutamate below threshold (3 μM) (24), cAMP concentrations were 91.6 ± 2% of forskolin alone and were not significantly affected by AM404 (84.4 ± 4.9%), AM403 (89.5 ± 2.4%), or bromcresol green (84.4 ± 3%) (n = 3).
38. E. Fride and R. Mechoulam, Eur. J. Pharmacol. 231, 313 (1993); P. B. Smith et al., J. Pharmacol. Exp. Ther. 270, 219 (1994).
39. E. Fride and R. Mechoulam, Eur. J. Pharmacol. 231, 313 (1993); P. B. Smith et al., J. Pharmacol. Exp. Ther. 270, 219 (1994).
40. The hot plate test (55.5°C) was carried out on male Swiss mice (25 to 30 g, Nossan, Italy) following standard procedures [F. Porreca, H. L. Mosberg, R. Hurst, V. J. Hruby, T. F. Burks, J. Pharmacol. Exp. Ther. 230, 341 (1994)]. Anandamide and AM404 were dissolved in 0.9% NaCl solution containing 20% dimethyl sulfoxide and injected intravenously at 20 mg/kg and 10 mg/kg, respectively. To determine whether cannabinoid receptors participate in the effect of anandamide, we administered anandamide (20 mg/kg intravenously) or anandamide plus SR141716-A (2 mg/kg, subcutaneously) to two groups of six mice each. In mice that received anandamide alone, latency to jump increased from 21.7 ± 1.5 s to 30.7 ± 0.8 s (P < 0.05, ANOVA) 20 min after injection. In contrast, in mice that received anandamide plus SR141716-A, the latency to jump was not affected (19.6 ± 3.1 s).
41. We thank E. di Tomaso and H. Cadas for help and E. Barker, L. Parsons, and P. Schweitzer for critical reading of the manuscript. Supported by the Neuroscience Research Foundation, which receives major support from Novartis.